This is a preview of subscription content, log in via an institution to check access.
Notes
I consider a view like this elsewhere (Flanigan, 2019).
Carroll also has a similar insight as Quong about bodily integrity and the significance of bodily rights in arguments against paternalism (Quong, 2022). So, some of my replies to Quong also respond to Carroll’s points about the rights-based arguments as well.
References
Ashford, E., & Mulgan , T. (2018). Contractualism. In E. N. Zalta (Ed.), The Stanford Encyclopedia of Philosophy. Retrieved June 7, 2022, from https://plato.stanford.edu/archives/sum2018/entries/contractualism/
Carroll, J. (2022). Is Visiting the Pharmacy Like Voting at the Poll? Behavioral Asymmetry in Pharmaceutical Freedom. HEC Forum, 34(3), 213–232. https://doi.org/10.1007/s10730-020-09414-8
Cato Institute. (2020). COVID-19 and the Right to Test. Retrieved June 7, 2022, from https://www.cato.org/events/covid-19-right-test
Earp, B. D., Lewis, J., & Hart, C. L. (2021). Racial justice requires ending the war on drugs. The American Journal of Bioethics, 21(4), 4–19. https://doi.org/10.1080/15265161.2020.1861364
FDA Commissioner. (2020). Right to try. Retrieved June 7, 2022, from https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try
Flanigan, J. (2017a). Patient-Driven drug development. In D. Ho (Ed.), Philosophical Issues in Pharmaceutics (pp. 9–27). New York: Springer
Flanigan, J. (2017b). Pharmaceutical Freedom: Why Patients Have a Right to Self Medicate. Oxford: Oxford University Press
Flanigan, J. (2019). Boundary problems and self ownership. Social Philosophy and Policy,36(2), 9–35. https://doi.org/10.1017/S0265052519000451
Flanigan, J. (2020). The Rawlsian mirror of justice. Philosophy and Public Issues (New Series),10(1), 69
Flanigan, J. (2021). The case for challenge trials. Cato Unbound. Retrieved June 7, 2022, from https://www.cato-unbound.org/2021/03/09/jessica-flanigan/case-challenge-trials
Flanigan, J. (2022). Scope of practice reform: Cost savings and patient empowerment. The Center for Growth and Opportunity. Retrieved June 7, 2022, from https://www.thecgo.org/research/scope-of-practice-reform-cost-savings-and-patient-empowerment/
Foddy, B., & J. Savulescu (2010). A liberal account of addiction. Philosophy Psychiatry & Psychology: PPP, 17(1), 1
Friedersdorf, C. (2021). The death toll of delay. The Atlantic, August 23, 2021. Retrieved June 7, 2022, from https://www.theatlantic.com/ideas/archive/2021/08/fda-delays-carry-death-toll/619871/
Guerrero, A. A. (2007). Don’t know, don’t kill: moral ignorance, culpability, and caution. Philosophical Studies, 136(1), 59–97
Hart, C. (2021). Drug Use for Grown-Ups: Chasing Liberty in the Land of Fear. New York: Penguin Press
Heilweil, R. (2021). Startups are betting on a psychedelic gold rush. Vox, October 13, 2021. Retrieved June 7, 2022, from https://www.vox.com/recode/22716491/psychedelics-ketamine-mental-health-research-fda
Horton, J. (2017). Aggregation, complaints, and risk. Philosophy & Public Affairs, 45(1), 54–81. https://doi.org/10.1111/papa.12084
Jackson, F., & Smith, M. (2006). Absolutist moral theories and uncertainty. The Journal of Philosophy, 103(6), 267–283
Kianpour, C. K. (2022). It only affects me: Pharmaceutical regulation and harm to others. HEC Forum, 34(3), 269–289. https://doi.org/10.1007/s10730-020-09409-5
Lazar, S. (2017). Deontological decision theory and agent-centered options. Ethics, 127(3), 579–609
Liu, S., Mello, M. M., & Kesselheim, A. S. (2021). Prospects for enforcing prohibitions on off-label drug promotion after United States v. Caronia: an analysis of litigated cases. Journal of Health Politics Policy and Law, 46(3), 487–504. https://doi.org/10.1215/03616878-8893571
Moller, D. (2011). Abortion and moral risk. Philosophy, 86(3), 425–443
Quong, J. (2022). On Flanigan’s Pharmaceutical Freedom. HEC Forum, 34(3), 257–268
Roberts, J. T. F. (2022). How to regulate the right to self-medicate. HEC Forum, 34(3), 233–255. https://doi.org/10.1007/s10730-020-09415-7
Williamson, T. (2017). Model-building in philosophy. In R. Blackford, & D. Broderick (Eds.), Philosophy’s Future: The Problem of Philosophical Progress (pp.159–71). New York: Wiley-Blackwell
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Flanigan, J. Revisiting Pharmaceutical Freedom. HEC Forum 34, 291–305 (2022). https://doi.org/10.1007/s10730-022-09483-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10730-022-09483-x